CytomX Therapeutics, Inc. (CTMX) to Release Quarterly Earnings on Wednesday
CytomX Therapeutics, Inc. (NASDAQ:CTMX) will be announcing its earnings results after the market closes on Wednesday, November 1st. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.
CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.30). The business had revenue of $8.75 million during the quarter, compared to analyst estimates of $4.95 million. CytomX Therapeutics had a negative net margin of 206.33% and a negative return on equity of 84.61%. On average, analysts expect CytomX Therapeutics to post $-1.44 EPS for the current fiscal year and $-1.41 EPS for the next fiscal year.
Shares of CytomX Therapeutics, Inc. (CTMX) opened at 20.09 on Wednesday. CytomX Therapeutics, Inc. has a 12 month low of $9.85 and a 12 month high of $24.67. The stock has a 50 day moving average price of $18.98 and a 200 day moving average price of $15.95. The firm’s market capitalization is $740.66 million.
Several research analysts have recently weighed in on CTMX shares. Cowen and Company restated a “buy” rating on shares of CytomX Therapeutics in a research note on Wednesday, June 28th. Bank of America Corporation boosted their price objective on shares of CytomX Therapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, October 4th. Nomura boosted their price objective on shares of CytomX Therapeutics to $44.00 and gave the stock a “buy” rating in a research note on Wednesday, October 4th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of CytomX Therapeutics in a research note on Wednesday, October 4th. Finally, BidaskClub upgraded shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, July 8th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $31.88.
COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/25/cytomx-therapeutics-inc-ctmx-to-release-quarterly-earnings-on-wednesday.html.
In related news, major shareholder Robert I. Tepper sold 24,777 shares of the company’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $24.34, for a total value of $603,072.18. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Debanjan Ray sold 2,500 shares of the company’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $15.00, for a total transaction of $37,500.00. Following the completion of the transaction, the chief financial officer now owns 19,626 shares in the company, valued at approximately $294,390. The disclosure for this sale can be found here. In the last quarter, insiders sold 177,794 shares of company stock worth $3,806,089. 8.00% of the stock is owned by company insiders.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.